Pyxis Oncology announces appointment of Kobayashi as CMO

Pyxis Oncology (PYXS) announced the appointment of Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer, CMO, effective November 27, 2023. Dr. Kobayashi brings extensive leadership experience in oncology clinical development and regulatory affairs. As CMO, Dr. Kobayashi will lead the Company’s clinical and regulatory operations, drive strategic growth, and play a key role in advancing Pyxis Oncology’s clinical pipeline. Most recently, Kobayashi served as Senior Vice President, Clinical Development at Kinnate Biopharma (KNTE).